NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Affini-T Therapeutics

Affini-T Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://affinittx.com/

Last Round

VC Round

Oct 15, 2024

Total Funding Raised

$180M

Company Overview

Affini-T Therapeutics is a biotechnology company that develops precision-engineered T-cell receptor (TCR) therapies targeting oncogenic driver mutations to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

T cell therapyoncogenic driver mutationssolid tumor oncologyKRAS targeted therapycell therapygene editingprecision medicineimmunotherapyTP53 targeted therapybiotech startupclinical stage biotechTCR therapydrug discoverysynthetic biologynext-gen oncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Affini-T Therapeutics Comparables

Compare Affini-T Therapeutics with similar companies based on industry and business-model similarity.

Affini-T Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OncoVanta Therapeutics
84%
Hula Therapeutics
83%
T-knife Therapeutics
81%

Affini-T Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 15, 2024
Series B ExtensionAug 1, 2024
Series AMar 22, 2022
SeedDec 24, 2020

Affini-T Therapeutics Investors

Notable investors and investment history

Affini-T Therapeutics investors
InvestorRounds
Agent CapitalSeries A
Vida VenturesSeries A
Parker Institute for Cancer ImmunotherapySeries A
Catalio Capital ManagementSeries A
Humboldt FundSeries A
Alexandria Venture InvestmentsSeries A
Leaps by BayerSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2025

    Will present at the 43rd Annual J.P. Morgan Healthcare Conference.

  • Aug 1, 2024

    Raised Series B Extension round with Metagenomi participating.

Affini-T Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Affini-T Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Affini-T Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range9
Year Founded2020
Last FundingOct 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.